Enlivex (ENLV) vs XORTX Therapeutics (XRTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Enlivex is the larger company by market cap ($2.0 million vs $1.9 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ENLV | XRTX |
|---|---|---|
| Share price | $1.05 | $0.839 |
| Market cap | $2.01M | $1.88M |
| 1-day change | -11.76% | -5.73% |
| P/E ratio (TTM) | 0.00 | — |
| Forward P/E | — | 1.05 |
| EPS (TTM) | $7,904.00 | $-2.09 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $1.24B | — |
| 52-week high | $434.40 | $3.60 |
| 52-week low | $1.00 | $0.81 |
| Distance from 52-week high | -99.76% | -76.69% |
| Analyst consensus | none | — |
| Avg. price target upside | +7519.05% | — |
| Average volume | 73.14K | 776.48K |
| Shares outstanding | 1.91M | 2.25M |
| Employees | 34 | — |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Enlivex
ENLV stock →Enlivex Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. It offers AllocetraTM, a cell therapy designed to restore macrophage homeostasis, as well as develops AllocetraTM intra-articular injection for the treatment of knee osteoarthritis, which is in phase 1/2 trial; intra-articular AllocetraTM in osteoarthritis of the temporomandibular joint (TMJ); and Allocetra-OTS for the treatment of organ failure in adult sepsis patients, which is in phase 2.
Health Care · Biotechnology: Pharmaceutical Preparations · 34 employees
About XORTX Therapeutics
XRTX stock →XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat hyperuricemia related diseases in Canada. It develops XRx-026, which is in Phase III for the treatment of gout; XRx-008, which is in Phase II for the treatment of autosomal dominant polycystic kidney disease; XRx-101, which is in Phase II for the treatment of acute kidney injury associated with respiratory virus infection, including sepsis and coronavirus; and XRX-225, which is in preclinical stage for the treatment of type 2 diabetic nephropathy, as well as VB4-P5, a program for the treatment and prevention of fibrosis in the kidney.
Health Care · Biotechnology: Pharmaceutical Preparations
ENLV vs XRTX FAQ
Which is bigger, Enlivex or XORTX Therapeutics?
Enlivex (ENLV) is larger, with a market capitalization of $2.01M compared with $1.88M for XORTX Therapeutics (XRTX).
Are Enlivex and XORTX Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.